BioStock: Cereno Scientific eyes an eventful 2022

Report this content

2021 was a year of significant progress for Cereno Scientific. The company received FDA IND acceptance and made the final preparations for its phase II clinical trial with CS1 in patients with pulmonary arterial hypertension. Cereno also broadened and powered up its development portfolio through collaboration agreements with the University of Michigan to bring two preclinical programmes through IND acceptance. BioStock spoke with the company’s CEO Sten R. Sörensen to get his thoughts on the eventful past year and his expectations for 2022.

Read the Q&A with Sten R. Sörensen at

This is a press release from BioStock - Connecting Innovation & Capital.


Documents & Links

Quick facts

BioStock: Cereno Scientific eyes an eventful 2022
Tweet this